Annual CFO
-$16.11 M
+$4.71 M+22.64%
December 31, 2023
Summary
- As of February 7, 2025, CYCC annual cash flow from operations is -$16.11 million, with the most recent change of +$4.71 million (+22.64%) on December 31, 2023.
- During the last 3 years, CYCC annual CFO has fallen by -$8.18 million (-103.08%).
- CYCC annual CFO is now -140.44% below its all-time high of -$6.70 million, reached on December 31, 2018.
Performance
CYCC Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$3.07 M
+$17.00 K+0.55%
September 30, 2024
Summary
- As of February 7, 2025, CYCC quarterly cash flow from operations is -$3.07 million, with the most recent change of +$17.00 thousand (+0.55%) on September 30, 2024.
- Over the past year, CYCC quarterly CFO has increased by +$843.00 thousand (+21.56%).
- CYCC quarterly CFO is now -1425.87% below its all-time high of -$201.00 thousand, reached on June 30, 2017.
Performance
CYCC Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$10.54 M
+$969.00 K+8.42%
September 30, 2024
Summary
- As of February 7, 2025, CYCC TTM cash flow from operations is -$10.54 million, with the most recent change of +$969.00 thousand (+8.42%) on September 30, 2024.
- Over the past year, CYCC TTM CFO has increased by +$5.57 million (+34.56%).
- CYCC TTM CFO is now -199.97% below its all-time high of -$3.52 million, reached on March 31, 2003.
Performance
CYCC TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
CYCC Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +22.6% | +21.6% | +34.6% |
| 3 y3 years | -103.1% | +55.3% | +49.6% |
| 5 y5 years | -140.4% | +55.3% | +49.6% |
CYCC Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +22.6% | -535.0% | +56.0% | -8.3% | +51.5% |
| 5 y | 5-year | -103.1% | +22.6% | -535.0% | +56.0% | -35.5% | +51.5% |
| alltime | all time | -140.4% | +46.1% | -1425.9% | +68.9% | -200.0% | +65.2% |
Cyclacel Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$3.07 M(-0.6%) | -$10.54 M(-8.4%) |
| Jun 2024 | - | -$3.08 M(+538.5%) | -$11.51 M(+18.3%) |
| Mar 2024 | - | -$483.00 K(-87.6%) | -$9.73 M(-39.6%) |
| Dec 2023 | -$16.11 M(-22.6%) | -$3.91 M(-3.1%) | -$16.11 M(-7.2%) |
| Sep 2023 | - | -$4.04 M(+209.3%) | -$17.37 M(-14.4%) |
| Jun 2023 | - | -$1.30 M(-81.0%) | -$20.30 M(-2.9%) |
| Mar 2023 | - | -$6.86 M(+32.7%) | -$20.91 M(+0.4%) |
| Dec 2022 | -$20.83 M(+12.3%) | -$5.17 M(-25.8%) | -$20.83 M(+3.1%) |
| Sep 2022 | - | -$6.97 M(+263.9%) | -$20.21 M(+3.9%) |
| Jun 2022 | - | -$1.92 M(-71.7%) | -$19.45 M(-10.6%) |
| Mar 2022 | - | -$6.78 M(+48.9%) | -$21.75 M(+17.3%) |
| Dec 2021 | -$18.54 M(+133.7%) | -$4.55 M(-26.7%) | -$18.54 M(+22.4%) |
| Sep 2021 | - | -$6.21 M(+47.3%) | -$15.14 M(+36.9%) |
| Jun 2021 | - | -$4.21 M(+18.2%) | -$11.06 M(+27.3%) |
| Mar 2021 | - | -$3.57 M(+209.5%) | -$8.69 M(+9.6%) |
| Dec 2020 | -$7.93 M(-16.0%) | -$1.15 M(-45.9%) | -$7.93 M(+0.4%) |
| Sep 2020 | - | -$2.13 M(+15.3%) | -$7.90 M(+1.5%) |
| Jun 2020 | - | -$1.85 M(-34.2%) | -$7.78 M(-9.2%) |
| Mar 2020 | - | -$2.81 M(+151.3%) | -$8.57 M(-9.3%) |
| Dec 2019 | -$9.45 M(+41.0%) | -$1.12 M(-44.5%) | -$9.45 M(-8.9%) |
| Sep 2019 | - | -$2.01 M(-23.7%) | -$10.37 M(+14.2%) |
| Jun 2019 | - | -$2.63 M(-28.5%) | -$9.08 M(+10.1%) |
| Mar 2019 | - | -$3.68 M(+80.9%) | -$8.25 M(+23.1%) |
| Dec 2018 | -$6.70 M(-10.4%) | -$2.04 M(+181.6%) | -$6.70 M(-2.7%) |
| Sep 2018 | - | -$723.00 K(-59.9%) | -$6.88 M(-7.1%) |
| Jun 2018 | - | -$1.80 M(-15.7%) | -$7.41 M(+27.6%) |
| Mar 2018 | - | -$2.14 M(-3.6%) | -$5.81 M(-22.3%) |
| Dec 2017 | -$7.48 M(-25.8%) | -$2.22 M(+77.7%) | -$7.48 M(-8.8%) |
| Sep 2017 | - | -$1.25 M(+521.4%) | -$8.20 M(-17.2%) |
| Jun 2017 | - | -$201.00 K(-94.7%) | -$9.91 M(-7.8%) |
| Mar 2017 | - | -$3.81 M(+29.5%) | -$10.74 M(+6.6%) |
| Dec 2016 | -$10.08 M(-30.3%) | -$2.94 M(-0.3%) | -$10.08 M(+2.7%) |
| Sep 2016 | - | -$2.95 M(+185.0%) | -$9.81 M(-10.5%) |
| Jun 2016 | - | -$1.04 M(-67.1%) | -$10.96 M(-13.7%) |
| Mar 2016 | - | -$3.15 M(+17.6%) | -$12.71 M(-12.1%) |
| Dec 2015 | -$14.46 M(-22.7%) | -$2.68 M(-34.8%) | -$14.46 M(-6.4%) |
| Sep 2015 | - | -$4.11 M(+47.8%) | -$15.45 M(-12.0%) |
| Jun 2015 | - | -$2.78 M(-43.3%) | -$17.55 M(-7.0%) |
| Mar 2015 | - | -$4.90 M(+33.6%) | -$18.88 M(+0.9%) |
| Dec 2014 | -$18.70 M(+2.8%) | -$3.67 M(-40.9%) | -$18.70 M(-8.4%) |
| Sep 2014 | - | -$6.21 M(+51.4%) | -$20.41 M(+24.9%) |
| Jun 2014 | - | -$4.10 M(-13.2%) | -$16.34 M(-6.9%) |
| Mar 2014 | - | -$4.73 M(-12.1%) | -$17.56 M(-3.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2013 | -$18.20 M(+51.1%) | -$5.38 M(+151.4%) | -$18.20 M(+19.1%) |
| Sep 2013 | - | -$2.14 M(-59.7%) | -$15.28 M(+0.2%) |
| Jun 2013 | - | -$5.31 M(-1.0%) | -$15.25 M(+11.8%) |
| Mar 2013 | - | -$5.37 M(+118.3%) | -$13.64 M(+13.3%) |
| Dec 2012 | -$12.04 M(-13.8%) | -$2.46 M(+16.7%) | -$12.04 M(-6.2%) |
| Sep 2012 | - | -$2.11 M(-43.1%) | -$12.84 M(-1.2%) |
| Jun 2012 | - | -$3.71 M(-1.8%) | -$13.00 M(-6.2%) |
| Mar 2012 | - | -$3.77 M(+15.7%) | -$13.86 M(-0.9%) |
| Dec 2011 | -$13.98 M(-12.9%) | -$3.26 M(+44.1%) | -$13.98 M(-3.3%) |
| Sep 2011 | - | -$2.26 M(-50.4%) | -$14.46 M(-1.8%) |
| Jun 2011 | - | -$4.56 M(+17.3%) | -$14.72 M(-2.9%) |
| Mar 2011 | - | -$3.89 M(+4.0%) | -$15.16 M(-5.5%) |
| Dec 2010 | -$16.04 M(+7.8%) | -$3.74 M(+48.1%) | -$16.04 M(+10.1%) |
| Sep 2010 | - | -$2.53 M(-49.5%) | -$14.57 M(+2.4%) |
| Jun 2010 | - | -$5.00 M(+4.9%) | -$14.22 M(-4.3%) |
| Mar 2010 | - | -$4.77 M(+110.4%) | -$14.86 M(-0.1%) |
| Dec 2009 | -$14.89 M(-50.2%) | -$2.27 M(+4.0%) | -$14.89 M(-21.6%) |
| Sep 2009 | - | -$2.18 M(-61.4%) | -$18.99 M(-11.3%) |
| Jun 2009 | - | -$5.64 M(+17.8%) | -$21.40 M(-13.9%) |
| Mar 2009 | - | -$4.79 M(-24.8%) | -$24.84 M(-16.9%) |
| Dec 2008 | -$29.91 M(+29.2%) | -$6.37 M(+38.9%) | -$29.91 M(+3.0%) |
| Sep 2008 | - | -$4.59 M(-49.5%) | -$29.04 M(-4.1%) |
| Jun 2008 | - | -$9.09 M(-7.8%) | -$30.30 M(+12.5%) |
| Mar 2008 | - | -$9.86 M(+78.9%) | -$26.93 M(+16.4%) |
| Dec 2007 | -$23.14 M(+14.7%) | -$5.51 M(-5.7%) | -$23.14 M(+10.1%) |
| Sep 2007 | - | -$5.84 M(+2.1%) | -$21.02 M(-2.4%) |
| Jun 2007 | - | -$5.72 M(-5.6%) | -$21.53 M(-9.9%) |
| Mar 2007 | - | -$6.06 M(+78.8%) | -$23.90 M(+18.5%) |
| Dec 2006 | -$20.17 M(+33.2%) | -$3.39 M(-46.7%) | -$20.17 M(-4.2%) |
| Sep 2006 | - | -$6.36 M(-21.4%) | -$21.06 M(+27.2%) |
| Jun 2006 | - | -$8.09 M(+246.2%) | -$16.55 M(+31.3%) |
| Mar 2006 | - | -$2.34 M(-45.4%) | -$12.61 M(-16.7%) |
| Dec 2005 | -$15.14 M(-28.2%) | -$4.28 M(+131.5%) | -$15.14 M(-17.2%) |
| Sep 2005 | - | -$1.85 M(-55.4%) | -$18.28 M(-17.2%) |
| Jun 2005 | - | -$4.14 M(-14.9%) | -$22.09 M(-0.6%) |
| Mar 2005 | - | -$4.87 M(-34.4%) | -$22.23 M(+5.4%) |
| Dec 2004 | -$21.09 M(+36.2%) | -$7.42 M(+31.3%) | -$21.09 M(+17.7%) |
| Sep 2004 | - | -$5.65 M(+31.9%) | -$17.92 M(+15.5%) |
| Jun 2004 | - | -$4.28 M(+14.9%) | -$15.51 M(-1.2%) |
| Mar 2004 | - | -$3.73 M(-12.4%) | -$15.70 M(+1.4%) |
| Dec 2003 | -$15.49 M | -$4.26 M(+31.4%) | -$15.49 M(+37.9%) |
| Sep 2003 | - | -$3.24 M(-27.5%) | -$11.23 M(+40.6%) |
| Jun 2003 | - | -$4.47 M(+27.2%) | -$7.99 M(+127.2%) |
| Mar 2003 | - | -$3.52 M | -$3.52 M |
FAQ
- What is Cyclacel Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Cyclacel Pharmaceuticals?
- What is Cyclacel Pharmaceuticals annual CFO year-on-year change?
- What is Cyclacel Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for Cyclacel Pharmaceuticals?
- What is Cyclacel Pharmaceuticals quarterly CFO year-on-year change?
- What is Cyclacel Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for Cyclacel Pharmaceuticals?
- What is Cyclacel Pharmaceuticals TTM CFO year-on-year change?
What is Cyclacel Pharmaceuticals annual cash flow from operations?
The current annual CFO of CYCC is -$16.11 M
What is the all time high annual CFO for Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals all-time high annual cash flow from operations is -$6.70 M
What is Cyclacel Pharmaceuticals annual CFO year-on-year change?
Over the past year, CYCC annual cash flow from operations has changed by +$4.71 M (+22.64%)
What is Cyclacel Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of CYCC is -$3.07 M
What is the all time high quarterly CFO for Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals all-time high quarterly cash flow from operations is -$201.00 K
What is Cyclacel Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, CYCC quarterly cash flow from operations has changed by +$843.00 K (+21.56%)
What is Cyclacel Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of CYCC is -$10.54 M
What is the all time high TTM CFO for Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals all-time high TTM cash flow from operations is -$3.52 M
What is Cyclacel Pharmaceuticals TTM CFO year-on-year change?
Over the past year, CYCC TTM cash flow from operations has changed by +$5.57 M (+34.56%)